公开(公告)号：US09637493B2

公开(公告)日：2017-05-02

申请号：US14652466

申请日：2013-12-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： Christopher Dinsmore ,  Francesc Xavier Fradera Llinas ,  Amit Ashokro Kudale ,  Michelle Machacek ,  Michael Hale Reutershan ,  Christopher Francis Thompson ,  B. Wesley Trotter ,  Liping Yang ,  Michael D. Altman ,  Stephane L. Bogen ,  Ronald J. Doll ,  Matthew E. Voss

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC classification number: C07D487/04

Abstract: The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

公开(公告)号：US09540377B2

公开(公告)日：2017-01-10

申请号：US14762827

申请日：2014-01-29

Applicant: Merck Sharp & Dohme Corp.

Inventor： Carolyn Michele Cammarano ,  Matthew P. Christopher ,  Christopher Dinsmore ,  Ronald J. Doll ,  Francesc Xavier Fradera Llinas ,  Chaomin Li ,  Michelle Machacek ,  Michelle Martinez ,  Latha G. Nair ,  Weidong Pan ,  Michael Hale Reutershan ,  Manami Shizuka ,  Dietrich P. Steinhuebel ,  Binyuan Sun ,  Christopher Francis Thompson ,  B. Wesley Trotter ,  Yaolin Wang ,  Liping Yang ,  Stephane L. Bogen ,  Matthew E. Voss ,  Jagannath Panda ,  Anthappan Tony Kurissery

IPC: A61K31/52 ,  C07D473/16 ,  C07D473/00 ,  C07D473/34 ,  C07D473/30

CPC classification number: C07D473/00 ,  C07D473/16 ,  C07D473/30 ,  C07D473/34

Abstract: The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract translation: 本发明提供如本文所述的2,6,7,8取代的嘌呤或其药学上可接受的盐。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。

公开(公告)号：US20140179680A1

公开(公告)日：2014-06-26

申请号：US14132946

申请日：2013-12-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： Matthew P. Christopher ,  Francesc Xavier Fradera Llinas ,  Michelle Machacek ,  Michelle Martinez ,  Michael Hale Reutershan ,  Manami Shizuka ,  Binyuan Sun ,  Christopher Francis Thompson ,  B. Wesley Trotter ,  Matthew E. Voss ,  Michael D. Altman ,  Stephane L. Bogen ,  Ronald J. Doll

IPC: C07D471/04 ,  C07D471/08 ,  C07D498/04

CPC classification number: C07D471/04 ,  C07D471/08 ,  C07D498/04 ,  C07D519/00

Abstract: The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Abstract translation: 本发明提供如本文所述的取代的咪唑并吡啶或其药学上可接受的盐或溶剂化物。 代表性化合物可用作HDM2蛋白的抑制剂。 还公开了包含上述化合物的药物组合物和使用其治疗癌症的潜在方法。